Literature DB >> 23503163

Impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed tuberculosis in South African children: a time-series analysis.

Ziyaad Dangor1, Alane Izu, Kelty Hillier, Fatima Solomon, Natalie Beylis, David P Moore, Marta C Nunes, Shabir A Madhi.   

Abstract

BACKGROUND: The HIV epidemic increased the burden of tuberculosis (TB) in sub-Saharan Africa. We evaluated the impact that scaling-up of the public-funded antiretroviral treatment (ART) program had on incidence of hospitalization for culture-confirmed and overall-TB in HIV-infected and HIV-uninfected children from 2005 to 2009.
METHODS: The study was undertaken in Soweto, South Africa, where ART coverage of HIV-infected children increased from 43% in 2005 to 84% by 2009. Trends in incidence of hospitalization for clinically diagnosed and culture-confirmed TB in children 3 months to <15 years of age, identified through laboratory and electronic databases, were analyzed by comparing crude incidence and regression analysis.
RESULTS: The incidence (per 100,000) of culture-confirmed TB declined by 63.1% from 2005 (69.8) compared with 2009 (25.8; P < 0.0001). This included a 70.6% reduction between 2005 and 2009 among HIV-infected children (incidence: 1566.3 versus 460.7, respectively; P < 0.0001) and 41.3% decrease in HIV-uninfected children (18.7 versus 11.0, respectively; P = 0.0003). The month-by-month rate of decline of culture-confirmed TB was 2.3% in HIV-infected and 1.1% in HIV-uninfected children over the study period. The residual burden of TB remained 42-fold greater in HIV-infected children, 78% of whom were severely immune compromised, compared with HIV-uninfected children by 2009.
CONCLUSION: Increase in ART coverage was associated with significant decline in TB hospitalizations in HIV-infected children. This reduction may also in part have been due to reduced Mycobacterium tuberculosis transmission resulting from increased ART access among HIV-infected adults, which may have contributed to the reduction of culture-confirmed TB in HIV-uninfected children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503163     DOI: 10.1097/INF.0b013e31828d9aa4

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

1.  Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.

Authors:  B Zeldow; S Kim; G McSherry; M F Cotton; P Jean-Philippe; A Violari; R Bobat; S Nachman; L M Mofenson; S A Madhi; C Mitchell
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

2.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

3.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

4.  Temporal association in hospitalizations for tuberculosis, invasive pneumococcal disease and influenza virus illness in South African children.

Authors:  Ziyaad Dangor; Alane Izu; David P Moore; Marta C Nunes; Fatima Solomon; Natalie Beylis; Anne von Gottberg; Johanna M McAnerney; Shabir A Madhi
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 5.  Tuberculosis and HIV co-infection in children.

Authors:  Elisabetta Venturini; Anna Turkova; Elena Chiappini; Luisa Galli; Maurizio de Martino; Claire Thorne
Journal:  BMC Infect Dis       Date:  2014-01-08       Impact factor: 3.090

Review 6.  Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.

Authors:  Linda Barlow-Mosha; Victor Musiime; Mary-Ann Davies; Andrew J Prendergast; Philippa Musoke; George Siberry; Martina Penazzato
Journal:  J Int AIDS Soc       Date:  2017-06-27       Impact factor: 5.396

7.  The Incremental Value of Repeated Induced Sputum and Gastric Aspirate Samples for the Diagnosis of Pulmonary Tuberculosis in Young Children With Acute Community-Acquired Pneumonia.

Authors:  David P Moore; Melissa M Higdon; Laura L Hammitt; Christine Prosperi; Andrea N DeLuca; Pedro Da Silva; Vicky L Baillie; Peter V Adrian; Azwifarwi Mudau; Maria Deloria Knoll; Daniel R Feikin; David R Murdoch; Katherine L O'Brien; Shabir A Madhi
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

Review 8.  Tuberculosis and pneumonia in HIV-infected children: an overview.

Authors:  Helena Rabie; Pierre Goussard
Journal:  Pneumonia (Nathan)       Date:  2016-11-24

Review 9.  Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.

Authors:  Sharon Nachman; Amina Ahmed; Farhana Amanullah; Mercedes C Becerra; Radu Botgros; Grania Brigden; Renee Browning; Elizabeth Gardiner; Richard Hafner; Anneke Hesseling; Cleotilde How; Patrick Jean-Philippe; Erica Lessem; Mamodikoe Makhene; Nontombi Mbelle; Ben Marais; Helen McIlleron; David F McNeeley; Carl Mendel; Stephen Murray; Eileen Navarro; E Gloria Anyalechi; Ariel R Porcalla; Clydette Powell; Mair Powell; Mona Rigaud; Vanessa Rouzier; Pearl Samson; H Simon Schaaf; Seema Shah; Jeff Starke; Soumya Swaminathan; Eric Wobudeya; Carol Worrell
Journal:  Lancet Infect Dis       Date:  2015-05-06       Impact factor: 25.071

Review 10.  Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children.

Authors:  Helena Rabie; Lisa Frigati; Anneke C Hesseling; Anthony J Garcia-Prats
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.